# An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

> **NCT05543252** · PHASE2 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 428 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Minzasolmin (UCB0599)

## Key facts

- **NCT ID:** NCT05543252
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-29
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-03-25
- **Target enrollment:** 428 (ACTUAL)
- **Why stopped:** Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543252, "An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05543252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*